5 results match your criteria: "University College London Medical School and Kings College Hospital[Affiliation]"
Hepatitis B prevalence in pregnant women in China: Progress and realities.
Lancet Reg Health West Pac
November 2021
University College London Medical School and Kings College Hospital, London, UK.
Hepatitis B virus infection.
Nat Rev Dis Primers
June 2018
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic infection in humans through immune anergy. Currently, 3.5% of the global population is chronically infected with HBV, although the incidence of HBV infections is decreasing owing to vaccination and, to a lesser extent, the use of antiviral therapy to reduce the viral load of chronically infected individuals.
View Article and Find Full Text PDFHepatitis B cure: From discovery to regulatory approval.
J Hepatol
October 2017
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States.
The majority of persons currently treated for chronic hepatitis B require long-term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardised appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials.
View Article and Find Full Text PDFHepatitis B cure: From discovery to regulatory approval.
Hepatology
October 2017
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
The majority of persons currently treated for chronic hepatitis B require long-term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials.
View Article and Find Full Text PDFBringing to an end mother-to-child transmission of hepatitis B: A role for quantitative hepatitis B surface antigen?
Hepatology
November 2016
Global Hepatitis Program, HIV Department World Health Organization, Geneva, Switzerland.